The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

Among the various aspects of the present disclosure is the provision of compositions and methods for treating hair regeneration disorders or conditions such as hair loss or thinning. An aspect of the present disclosure provides for a method of treating hair loss, promoting hair growth, or treating hair loss, such as alopecia or telogen effluvium, comprising administering a TRPV4 activating agent to a subject.

Among the various aspects of the present disclosure is the provision of compositions and methods for treating hair regeneration disorders or conditions such as hair loss or thinning. An aspect of the present disclosure provides for a method of treating hair loss, promoting hair growth, or treating hair loss, such as alopecia or telogen effluvium, comprising administering a TRPV4 activating agent to a subject.

Problem to be Solved

Provided is a method for manufacturing a pharmaceutical preparation, which safely and simply enables uniformization of contents of a small amount of a drug.

[Solution]

The method for manufacturing the pharmaceutical preparation includes: using a liquid for dispensing, the liquid containing a drug; and a first application step of applying the drug to a surface of a tablet or a capsule by a dispensing method. In addition, a pharmaceutical preparation according to the present invention includes: a base; and a drug which is applied to a surface of the base by a dispensing method, and the base is a tablet or a capsule.

Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:

##STR00001##

Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:

##STR00001##

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.